ABEO
Price
$5.43
Change
+$0.07 (+1.31%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
274.85M
52 days until earnings call
PBIGF
Price
$0.18
Change
+$0.01 (+5.88%)
Updated
Sep 16 closing price
Capitalization
73.23M
Interact to see
Advertisement

ABEO vs PBIGF

Header iconABEO vs PBIGF Comparison
Open Charts ABEO vs PBIGFBanner chart's image
Abeona Therapeutics
Price$5.43
Change+$0.07 (+1.31%)
Volume$21.74K
Capitalization274.85M
Paradigm Biopharmaceuticals
Price$0.18
Change+$0.01 (+5.88%)
Volume$2.25K
Capitalization73.23M
ABEO vs PBIGF Comparison Chart in %
Loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBIGF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABEO vs. PBIGF commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a Buy and PBIGF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (ABEO: $5.43 vs. PBIGF: $0.18)
Brand notoriety: ABEO and PBIGF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 69% vs. PBIGF: 26%
Market capitalization -- ABEO: $274.85M vs. PBIGF: $73.23M
ABEO [@Biotechnology] is valued at $274.85M. PBIGF’s [@Biotechnology] market capitalization is $73.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 1 FA rating(s) are green whilePBIGF’s FA Score has 0 green FA rating(s).

  • ABEO’s FA Score: 1 green, 4 red.
  • PBIGF’s FA Score: 0 green, 5 red.
According to our system of comparison, ABEO is a better buy in the long-term than PBIGF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 4 TA indicator(s) are bullish while PBIGF’s TA Score has 4 bullish TA indicator(s).

  • ABEO’s TA Score: 4 bullish, 6 bearish.
  • PBIGF’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, PBIGF is a better buy in the short-term than ABEO.

Price Growth

ABEO (@Biotechnology) experienced а +0.93% price change this week, while PBIGF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.14%. For the same industry, the average monthly price growth was +9.25%, and the average quarterly price growth was +54.64%.

Reported Earning Dates

ABEO is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+4.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABEO($275M) has a higher market cap than PBIGF($73.2M). ABEO YTD gains are higher at: -3.770 vs. PBIGF (-33.169). ABEO has higher annual earnings (EBITDA): 80M vs. PBIGF (-15.46M).
ABEOPBIGFABEO / PBIGF
Capitalization275M73.2M376%
EBITDA80M-15.46M-517%
Gain YTD-3.770-33.16911%
P/E Ratio8.38N/A-
Revenue400KN/A-
Total Cash226MN/A-
Total Debt24.1MN/A-
FUNDAMENTALS RATINGS
ABEO vs PBIGF: Fundamental Ratings
ABEO
PBIGF
OUTLOOK RATING
1..100
5824
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
86
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
2098
PRICE GROWTH RATING
1..100
6465
P/E GROWTH RATING
1..100
78100
SEASONALITY SCORE
1..100
5017

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABEO's Valuation (76) in the Pharmaceuticals Generic industry is in the same range as PBIGF (86) in the null industry. This means that ABEO’s stock grew similarly to PBIGF’s over the last 12 months.

ABEO's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as PBIGF (100) in the null industry. This means that ABEO’s stock grew similarly to PBIGF’s over the last 12 months.

ABEO's SMR Rating (20) in the Pharmaceuticals Generic industry is significantly better than the same rating for PBIGF (98) in the null industry. This means that ABEO’s stock grew significantly faster than PBIGF’s over the last 12 months.

ABEO's Price Growth Rating (64) in the Pharmaceuticals Generic industry is in the same range as PBIGF (65) in the null industry. This means that ABEO’s stock grew similarly to PBIGF’s over the last 12 months.

ABEO's P/E Growth Rating (78) in the Pharmaceuticals Generic industry is in the same range as PBIGF (100) in the null industry. This means that ABEO’s stock grew similarly to PBIGF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEOPBIGF
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
29%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
65%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
37%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
35%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
39%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
47%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
N/A
Declines
ODDS (%)
Bearish Trend 10 days ago
87%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
25%
Aroon
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
54%
View a ticker or compare two or three
Interact to see
Advertisement
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBIGF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CFOO0.66N/A
N/A
China Foods Holdings Ltd.
AIRRF0.83N/A
N/A
Aurion Resources Ltd.
DTNOF1.50N/A
N/A
DNO ASA
MSBHF24.33N/A
N/A
Mitsubishi Corp.
DVCMY6.41N/A
N/A
DAVIDE CAMPARI MILANO N V

ABEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABEO has been loosely correlated with ZYME. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ABEO jumps, then ZYME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
-3.42%
ZYME - ABEO
47%
Loosely correlated
-0.86%
ELVN - ABEO
45%
Loosely correlated
-3.28%
OCUL - ABEO
43%
Loosely correlated
-2.55%
DYN - ABEO
42%
Loosely correlated
-4.48%
CRNX - ABEO
42%
Loosely correlated
+2.02%
More

PBIGF and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBIGF has been loosely correlated with ABEO. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if PBIGF jumps, then ABEO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBIGF
1D Price
Change %
PBIGF100%
N/A
ABEO - PBIGF
34%
Loosely correlated
+1.31%
STTK - PBIGF
21%
Poorly correlated
-0.44%
ARWR - PBIGF
21%
Poorly correlated
+3.58%
OXBDF - PBIGF
7%
Poorly correlated
N/A
PTCHF - PBIGF
6%
Poorly correlated
N/A
More